SEC Filings
Rapport's Bipolar Mania Drug Beat Placebo By 3.1 Points, But Twice As Many Quit Treatment
An 8-K shows RAP-219 met its main goal in a 253-adult mid-stage trial, with 24.6% stopping treatment versus 11.8% on placebo.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
An 8-K shows RAP-219 met its main goal in a 253-adult mid-stage trial, with 24.6% stopping treatment versus 11.8% on placebo.
SEC Filings
The five-tranche private offering carries coupons from 5.100% to 5.800% and is not conditioned on the Kenvue deal closing.
Earnings
Production at Ying resumed and ended the quarter at a 90% operating rate, and full financial results are due November 5 after the close.
SEC Filings
Most of the 2,424,529 shares sit in client funds run by independently managed Harel subsidiaries, the Schedule 13G says.
Earnings
Berkley's chief executive sees liability lines as the opening, with reinsurance premiums down 11.6% to $369 million in the third quarter.
Insider Trades
His 10b5-1 sales since July 21 now total 324,000 shares and $34.6 million, and he reports 127,994 shares after Thursday's sale.
Deals
The deal, targeted to close in the first half of 2027, includes a $105 million termination fee payable by Tradeweb in certain cases.
Earnings
The drugmaker will hold a 4:30 p.m. ET call with its CEO and CFO, and a webcast replay will stay up for 60 days.
SEC Filings
An 8-K filed Monday shows $159.3 million of a separate $231.0 million Boeing pre-delivery facility is still undrawn.
SEC Filings
The Series O depositary shares carry a $1,000 liquidation preference, and the term sheet shows $1,237,500,000 in net proceeds before expenses.
Deals
The European Commission and New York regulators have acted, but the take-private still needs other regulatory approvals before it can close.
Earnings
Nine-month net income at the Rosemont, Illinois bank holding company rose 17%, with loans and deposits each up 8% annualized in the quarter.